BUZZ-Australia's LTR Pharma gains on US deal for Roxus

** Shares of Australia's LTR Pharma LTP.AX rise as much as 25.9% to A$0.535, their biggest gain since June 5

** The clinical-stage biopharma firm executed a binding term sheet with U.S.-based pharmacy operator Strive Specialities

** The binding term sheet establishes exclusive U.S. pharmacy fulfillment rights for ROXUS, an intranasal treatment for erectile dysfunction

** Around 2.1 mln shares change hands, nearly 4x 30-day average

** LTP down 31.3% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.